For breakthrough-designated devices, it compresses the gap between FDA authorisation and Medicare coverage from over a year to as little as two months. That is not a tweak to existing process. That is a structural shift in how quickly an innovative device can reach the patients who need it.
For anyone who has watched a cleared device sit in commercial limbo while the reimbursement clock runs, this matters. The companies that have done the evidence work, built the health economic case, and engaged payers early now have a pathway that rewards that preparation rather than making them wait regardless. That is how policy should work.
It is also a signal that the relationship between regulatory authorisation and coverage determination is being taken seriously at the highest level. The two agencies moving together, rather than sequentially, is the right architecture for an industry where timing is everything.
Sixty days of public comment are open. Worth engaging with.